Small Molecules

An insight into the research fuelling developments for universal cancer immunotherapies

Researchers use genome mining and bioengineering techniques to develop sustainable saponin-based vaccine adjuvants

The wait is over. Our annual celebration of the pharma industry’s most influential individuals has returned!

Oligonucleotides are a complex but promising new modality in therapeutics. Director of New Modalities at CatSci Nigel Richardson explains why.

A start up company explains how their platform is helping to boost RNA therapeutics.

These fungi have some real nerve (developing properties).

Pipelines are changing, and chemical complexity is on the rise. What can pharma manufacturers do about it?

Lawsuit from GenBioPro is the first of its kind – but other cases are likely to follow.

Water is the giver of life, but could it be a giver of untold medicines too?

Though key hurdles remain, there is huge potential for mRNA-based therapeutics to tackle areas of unmet need.